ASH Lymphoma eBook
Focus on ASH Lymphoma 2023v2.indd
Read More
Zynlonta – Display Banners Conference – FEB – 28651
CAR-Hematotox Score Predicts Toxicity, Infection & Clinical Outcomes in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read More
Metabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read More
Odronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read More
High-Dose Chemotherapy Plus ASCT Superior to Standard Immune-Chemotherapy in Primary CNS Lymphoma
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read More
Ibrutinib Added to ASCT Improves Clinical Outcomes in Mantle Cell Lymphoma
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read MoreHealth and Safety Protocols
Key Protocols: Vaccination will be required for all in-person meeting attendees. ASH is offering complimentary* medical evacuation and quarantine support coverage. Proof of a negative COVID-19 test is not required for in-person...
Read MoreASH Foundation Run & Walk
The ASH Foundation Run & Walk will start and finish on Convention Center Boulevard and Julia Street, head toward the Riverwalk near the Audubon Aquarium of the Americas, and go through Woldenberg Park. Schedule: 7:00 a.m....
Read MoreFriday Satellite Symposia
FSS are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company. Morning Topics: A Thread To Pull: Unraveling The...
Read More
African American Patients with Diffuse Large B-Cell Lymphoma: Predictors of Inferior Survival
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read MoreDiffuse Large B-Cell Lymphoma Patients: Impact of Circulating Lymphoma at Diagnosis on Outcomes
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various prognostic factors were known, including the revised international prognostic index (R-IPI), MYC/BCL2 overexpression by IHC,...
Read More
Predictor of Response to Loncastuximab Tesirine: Expression by IHC
A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...
Read More
Relapsed/Refractory DLBCL Patients Treated with Loncastuximab Tesirine: Predicting Outcome by Metabolic Tumor Volume
For tailored therapy selection and result optimization in diffuse large B-cell lymphoma (DLBCL),...
Read More